New more sensitive diagnostics protect transplanted kidney
With new more sensitive diagnostics, rejection of a transplanted kidney can be detected earlier,...
News | February 10, 2023
We are pleased to welcome Vertitas Corporation as a new distributor of the Devyser portfolio for the Japanese market. Veritas is a trading company specializing in biotechnology with a long history and deep understanding of the Japanese biotechnology market. They will be an acknowledged partner for all Devyser products.
Veritas will start to introduce Devyser NGS tests to Japanese customers. Mr. Yuya Yukozawa, Manager at the Bioscience Department at Veritas, is of the opinion that the simplicity of Devysers NGS workflow will be appealing to the Japanese market which today uses other more complicated and time-consuming methods.
“The Devyser NGS kits have proven to be easy to use and require very little hands-on time for lab personnel and this will be important for Japanese users of these kits, says Mr. Yukozawa”.
Introducing new technologies is generally demanding in Japan but the strong scientific and technical knowledge of Vertitas sales, marketing, and technical support staff will allow us to enter the promising Japanese market.
“Vertitas network will provide us with the market penetration needed to reach full sales potential. We are confident that Veritas will help us leverage our position in the Japanese market, says Theis Kipling, Chief Commercial Officer at Devyser.”
We, at Devyser, are once again pioneering in a new market to strive for a world where personalized medicine is universally available thanks to simplified and reliable genetic tests.
With new more sensitive diagnostics, rejection of a transplanted kidney can be detected earlier,...
Read More
Hematopoietic stem cell transplantation (HSCT) is the only curative treatment for patients with...
Read More
Relapse of the underlying malignant disease is a major complication after hematopoietic stem cell...
Read More
Read More